Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RP3

Oncolytic virus · Kills target cells · developed by Replimune

Phase 2 Most advanced trial (none active)
REPL Developer
1 Registered trials

What is RP3?

RP3 is a genetically modified herpes simplex type 1 virus, classed as an oncolytic virus, studied in refractory metastatic colorectal cancer that is mismatch repair proficient and microsatellite stable.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oncolytic virus
Mechanism
Kills target cells
Therapy area
Oncology
Developer
Replimune, Inc. (REPL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05733611 Phase 2 Refractory Metastatic Colorectal Cancer Terminated REPL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MSSpMMRRefractory Metastatic Colorectal Cancer

More from Replimune

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the REPL page.

Follow REPL, the company behind RP3

See REPL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REPL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.